Quantum Genomics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QNNTF research report →
Price Chart
About the company
Quantum Genomics S. A. , a biopharmaceutical enterprise headquartered in Paris, France, was established in 2005.
- CEO
- Mathieu Bigois
- IPO
- 2021
- Employees
- 3
- HQ
- Paris, FR
Get TickerSpark's AI analysis on QNNTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.96M
- P/E
- -0.55
- Fwd P/E
- 0.02
- PEG
- -0.01
- P/S
- 499945.80
- P/B
- -2.05
- EV/EBITDA
- -4.99
- Div Yield
- 0.00%
- Gross Margin
- -11453070.00%
- Op Margin
- -14728350.00%
- Net Margin
- -88926030.00%
- ROE
- 880.77%
- ROIC
- -153.05%
Latest fiscal year · YoY change
- Revenue
- $10-99.9%
- Gross Profit
- $-1,145,307+19.3%
- Op Income
- $-1,472,835
- Net Income
- $-8,892,603-180.4%
- EPS
- $-0.13-42.9%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.10
- 52W Low
- $0.10
- 50D MA
- $0.10
- 200D MA
- $0.10
- Beta
- 0.16
- RSI (14)
- 0
- Avg Volume
- 1.91K
No earnings-call transcripts are available for QNNTF yet.
- Free Float
- 91.1%
- Shares Outstanding
- 69.62M
- Float Shares
- 63.44M
Our QNNTF coverage
Recent articles, reports, and earnings notes.
No research on QNNTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QNNTF report →Comparing TELA Bio (NASDAQ:TELA) & Quantum Genomics (OTCMKTS:QNNTF)
defenseworld.net · Mar 1
Quantum Genomics and its Partners Reach a New Stage of Development in Asia
globenewswire.com · Oct 7
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
globenewswire.com · Aug 27
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat
globenewswire.com · Jul 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.